Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Bases de datos
Tipo de estudio
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioorg Med Chem Lett ; 20(9): 2903-7, 2010 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-20382019

RESUMEN

A series of 4-(3-biaryl)quinolines with sulfone substituents on the terminal aryl ring (8) was prepared as potential LXR agonists. High affinity LXRbeta ligands with generally modest binding selectivity over LXRalpha and excellent agonist potency in LXR functional assays were identified. Many compounds had LXRbeta binding IC(50) values <10 nM while the most potent had EC(50) values <1.0 nM in an ABCA1 mRNA induction assay in J774 mouse cells with efficacy comparable to T0901317. Sulfone 8a was further evaluated in LDL (-/-) mice and shown to reduce atherosclerotic lesion progression.


Asunto(s)
Receptores Nucleares Huérfanos/agonistas , Quinolinas/química , Sulfonas/química , Animales , Aterosclerosis/tratamiento farmacológico , Sitios de Unión , Línea Celular , Simulación por Computador , Humanos , Lipoproteínas LDL/deficiencia , Lipoproteínas LDL/genética , Lipoproteínas LDL/metabolismo , Receptores X del Hígado , Ratones , Ratones Noqueados , Microsomas/metabolismo , Receptores Nucleares Huérfanos/metabolismo , Ratas , Relación Estructura-Actividad , Sulfonas/síntesis química , Sulfonas/uso terapéutico
2.
Bioorg Med Chem Lett ; 20(1): 209-12, 2010 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-19932617

RESUMEN

A series of 4-(3-aryloxyaryl)quinolines with sulfone substituents on the terminal aryl ring (7) was prepared as LXR agonists. High affinity LXR ligands with excellent agonist potency and efficacy in functional assays of LXR activity were identified. In general, these sulfone agonists were equal to or superior to previously described alcohol and amide analogs in terms of affinity, functional potency, and microsomal stability. Many of the sulfones had LXRbeta binding IC(50) values <10nM while the most potent compounds in an ABCA1 mRNA induction assay in J774 mouse cells had EC(50) values <10nM and were as efficacious as T0901317.


Asunto(s)
Receptores Nucleares Huérfanos/agonistas , Quinolinas/química , Sulfonas/química , Transportador 1 de Casete de Unión a ATP , Transportadoras de Casetes de Unión a ATP/genética , Transportadoras de Casetes de Unión a ATP/metabolismo , Animales , Sitios de Unión , Línea Celular , Simulación por Computador , Humanos , Hidrocarburos Fluorados/química , Hidrocarburos Fluorados/farmacología , Enlace de Hidrógeno , Receptores X del Hígado , Ratones , Microsomas Hepáticos/metabolismo , Receptores Nucleares Huérfanos/metabolismo , Quinolinas/síntesis química , Quinolinas/farmacología , Ratas , Relación Estructura-Actividad , Sulfonamidas/química , Sulfonamidas/farmacología , Sulfonas/síntesis química , Sulfonas/farmacología
3.
Chirality ; 20(6): 762-70, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18200591

RESUMEN

During the last thirty years, concern over stereoselectivity of drug action has drawn a great deal of interest within the pharmaceutical field due to an improved understanding of the pharmacology and pharmacokinetics of enantiomers. Developing single enantiomers versus racemates or introducing a single enantiomer following the development of the racemic mixture appears to be the new trend. The intellectual property status of single enantiomers from racemates may be unclear. Drug discoverers and patent attorneys must examine the examples of the past to establish an appropriate pathway towards the development and intellectual property protection of chiral drugs. The review will focus on the patenting of an enantiomer in view of the prior art disclosure for the racemic mixture.


Asunto(s)
Industria Farmacéutica/legislación & jurisprudencia , Patentes como Asunto/legislación & jurisprudencia , Preparaciones Farmacéuticas/química , Diseño de Fármacos , Propiedad Intelectual , Preparaciones Farmacéuticas/síntesis química , Estereoisomerismo , Estados Unidos
4.
Org Lett ; 11(5): 1183-5, 2009 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-19209924

RESUMEN

An efficient and mild method to couple aryl bromides and activated non-allylic alcohols in a Heck reaction with tandem isomerization to selectively afford high yields of 1,5-diarylalkan-1-ones has been developed. Mechanistic insight was gained through NMR studies of products derived from deuterium-labeled intermediates.


Asunto(s)
Alcoholes Bencílicos/química , Bromuros/química , Paladio/química , Catálisis , Espectroscopía de Resonancia Magnética , Estructura Molecular , Estereoisomerismo
5.
Bioorg Med Chem Lett ; 17(1): 118-22, 2007 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-17049855

RESUMEN

The design, synthesis, and biological evaluation of the 2-phenyl-isoindole-1,3-diones will be discussed. Detailed modeling studies with X-ray support were used to understand the ligand binding orientation and observed selectivity.


Asunto(s)
Receptor beta de Estrógeno/agonistas , Indoles/química , Ftalimidas/química , Cristalografía por Rayos X , Receptor beta de Estrógeno/química , Humanos , Indoles/síntesis química , Ligandos , Ftalimidas/síntesis química
6.
Bioorg Med Chem Lett ; 12(23): 3487-90, 2002 Dec 02.
Artículo en Inglés | MEDLINE | ID: mdl-12419390

RESUMEN

A new series of 3,3-disubstituted-5-aryloxindoles has been synthesized and evaluated for progesterone receptor antagonist (PR) activity in a T47D cell alkaline phosphatase assay and for their ability to bind PR in competition binding studies. In this communication, the synthesis and structure-activity relationships (SARs) of various 3,3-substituents are discussed where it is clear that small alkyl and spiroalkyl groups are required to achieve better PR antagonist activity.


Asunto(s)
Ciclohexanos/química , Ciclohexanos/farmacología , Indoles/química , Indoles/farmacología , Receptores de Progesterona/antagonistas & inhibidores , Fosfatasa Alcalina/metabolismo , Animales , Unión Competitiva , Bioensayo , Neoplasias de la Mama , Decidua/efectos de los fármacos , Femenino , Humanos , Concentración 50 Inhibidora , Ratas , Receptores de Progesterona/metabolismo , Relación Estructura-Actividad , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA